Literature DB >> 6322004

Chronic benzodiazepine treatment decreases postsynaptic GABA sensitivity.

D W Gallager, J M Lakoski, S F Gonsalves, S L Rauch.   

Abstract

Benzodiazepines exert most of their pharmacological effects by a selective facilitation of the postsynaptic actions of GABA. Clinical, behavioural and electrophysiological studies have shown reduced drug response following chronic benzodiazepine administration. We present here electrophysiological evidence for decreased postsynaptic sensitivity to GABA following chronic benzodiazepine administration as measured by the direct iontophoretic application of GABA and serotonin onto serotonergic cells in the midbrain dorsal raphe nucleus (DRN), known to receive GABAergic input. The subsensitivity to GABA was found to be dose dependent and was seen when diazepam administration was three weeks or longer. Further, acute injection of the specific benzodiazepine antagonist, Ro15-1788, was found to reverse rapidly the decrease in GABA sensitivity observed in chronically diazepam-treated animals without altering GABA sensitivity in vehicle-treated rats. Decreased response to chronic benzodiazepines does not appear to be consistently related to alterations in the number or affinity of receptors for benzodiazepines. Our studies of radioligand-binding showed a decrease in the ability of GABA to enhance benzodiazepine binding in cerebral cortical membranes from chronic diazepam-treated animals without significant changes in benzodiazepine binding site density or affinity.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6322004     DOI: 10.1038/308074a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  44 in total

1.  Rate of change of blood concentrations is a major determinant of the pharmacodynamics of midazolam in rats.

Authors:  A Cleton; D Mazee; R A Voskuyl; M Danhof
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

2.  Silent GABAA synapses during flurazepam withdrawal are region-specific in the hippocampal formation.

Authors:  P Poisbeau; S R Williams; I Mody
Journal:  J Neurosci       Date:  1997-05-15       Impact factor: 6.167

3.  GABAA Receptor Density Is Not Altered by a Novel Herbal Anxiolytic Treatment.

Authors:  Ravid Doron; Avital Sever; Assaf Handelsman; Roni Toledano; Motty Franko; Yafit Hirshler; Alon Shamir; Or Burstein; Moshe Rehavi
Journal:  J Mol Neurosci       Date:  2018-05-08       Impact factor: 3.444

Review 4.  Modulation and polytypic signaling in GABAergic transmission.

Authors:  J L Schlichting
Journal:  Neurochem Res       Date:  1990-02       Impact factor: 3.996

5.  Characterisation of the phenomenon of "one-trial tolerance" to the anxiolytic effect of chlordiazepoxide in the elevated plus-maze.

Authors:  S E File; P S Mabbutt; P K Hitchcott
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 6.  Molecular and cellular mechanisms of GABA/benzodiazepine-receptor regulation: electrophysiological and biochemical studies.

Authors:  M Farrant; T T Gibbs; D H Farb
Journal:  Neurochem Res       Date:  1990-02       Impact factor: 3.996

Review 7.  The role of the brain stem in generalized epileptic seizures.

Authors:  C L Faingold
Journal:  Metab Brain Dis       Date:  1987-06       Impact factor: 3.584

8.  Benzodiazepine treatment induces subtype-specific changes in GABA(A) receptor trafficking and decreases synaptic inhibition.

Authors:  Tija C Jacob; Guido Michels; Liliya Silayeva; Julia Haydon; Francesca Succol; Stephen J Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-22       Impact factor: 11.205

9.  Ethanol promotes clathrin adaptor-mediated endocytosis via the intracellular domain of δ-containing GABAA receptors.

Authors:  Claudia Gonzalez; Stephen J Moss; Richard W Olsen
Journal:  J Neurosci       Date:  2012-12-05       Impact factor: 6.167

10.  Molecular mechanisms of benzodiazepine-induced down-regulation of GABAA receptor alpha 1 subunit protein in rat cerebellar granule cells.

Authors:  M J Brown; D R Bristow
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.